Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh (AMGN34) Stock Price & Analysis

AMGN34 Stock Chart & Stats

R$91.17R$2.61(2.95%)

At close: Oct 30

Day’s Range: BRL 90.55 - BRL 91.74
52-Week Range: BRL 0.01 - BRL 91.74
Previous Close: BRL 88.56
Volume: N/A
Average Volume (3M): 415
Market Cap: BRL 1.37T
Enterprise Value: BRL 1.23T
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): 30390.0
Beta: -0.33
Next Earnings: Nov 03, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: 1.37%

Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh News

Amgen says video ad for Vectibix cited by FDA never publicly disseminated

As previously reported, in a letter to Amgen (AMGN) Chairman and CEO, the FDA said: “The Office of Prescription Drug Promotion of the U.S. Food and Drug Administration has reviewed

4d agoAMGN AMG

Amgen to present results from Phase 3 OASIZ-301 study at ACR

Amgen (AMGN) will present late-breaking results from the Phase 3 OASIZ-301 study evaluating dazodalibep in adults living with Sjogren’s disease and moderate-to-severe systemic disease activity. Dazodalibep is a CD40L antagonist

4d agoAMGN AMG

Amgen names David Gibbs to board of directors

Amgen (AMGN) announced the appointment of David Gibbs to its Board of Directors, effective immediately. Gibbs will serve on the Board’s Audit Committee and Compensation and Management Development Committee. Gibbs

5d agoUA PEP

Morning Movers: Verizon lower following third quarter results

Stock futures are higher as investors prepare for an important week of Big Tech earnings, the Federal Reserve’s interest-rate decision and fresh inflation data. Markets are attempting to stabilize after

6d agoVZ BOH

Amgen: Imdelltra Data Encouraging but Commercial Uncertainties Keep Shares Above Unchanged $328 Target, Underperform Rating Maintained

Bank of America Securities analyst Tazeen Ahmad maintained a Sell rating on Amgen today and set a price target of $328.00. Tazeen Ahmad has given his Sell rating due to

6d agoAMGN AMG

Amgen announces Phase 3 results of Imdelltra with AstraZeneca’s Imfinzi

Amgen (AMGN) announced an interim Phase 3 results showing that Imdelltra in combination with AstraZeneca’s (AZN) Imfinzi reduced the risk of death by 58% as a first-line maintenance treatment for

6d agoAZN AMGN

Amgen price target raised to $480 from $450 at Oppenheimer

Oppenheimer analyst Jay Olson raised the firm’s price target on Amgen (AMGN) to $480 from $450 and keeps an Outperform rating on the shares ahead of quarterly results. The firm

1w agoAMGN AMG

Amgen price target raised to $400 from $380 at Barclays

Barclays raised the firm’s price target on Amgen (AMGN) to $400 from $380 and keeps an Equal Weight rating on the shares as part of a Q3 earnings preview. The

1w agoAMGN AMG

AstraZeneca reports full results from Phase 3 CROSSING trial of Tezspire

Full results from the “positive” Phase 3 CROSSING trial showed that AstraZeneca (AZN) and Amgen’s (AMGN) Tezspire demonstrated statistically significant and clinically meaningful improvements in the co-primary endpoints of histologic

1w agoAZN AMGN

AstraZeneca, Amgen announce TEZSPIRE showed ‘significant’ improvements

Full results from the Phase III CROSSING trial showed that AstraZeneca (AZN) and Amgen’s (AMGN) TEZSPIRE demonstrated statistically significant and clinically meaningful improvements in the co-primary endpoints of histologic remission

1w agoAZN AMGN

Mattel appoints Griffith as Chief Financial Officer, Board Director

Mattel (MAT) announced the appointment of Peter Griffith as Chief Financial Officer, effective October 20, 2026. Griffith succeeds Paul Ruh, who will serve in an advisory role through the end

1w agoMAT AMGN

Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX)

WSW, NY, October 7th, 2026, FinanceWire The former Gilead and Amgen commercial leader takes her seat as Entera’s Phase 3 trial nears its initiation. Entera Bio Ltd. (NASDAQ:ENTX), a clinical-stage

3w agoLLY AMGN

Amgen: Strengthening Pipeline and Long-Term Growth Upside Support Buy Rating and Unchanged $450 Price Target

Salveen Richter, an analyst from Goldman Sachs, maintained the Buy rating on Amgen. The associated price target remains the same with $450.00. Salveen Richter has given his Buy rating due

1M agoAMGN AMG

Amgen Underperform Maintained as Dazodalibep Data Uncertainty Limits Upside; $317 Price Target Unchanged

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Sell rating on Amgen. The associated price target remains the same with $317.00. Tazeen Ahmad has given his Sell

1M agoAMGN AMG

AMGN34 FAQ

What was Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh’s price range in the past 12 months?

Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh lowest stock price was R$0.01 and its highest was R$91.74 in the past 12 months.

What is Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh’s market cap?

Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh’s market cap is R$1.37T.

When is Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh’s earnings last quarter?

Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh released its earnings results on Aug 04, 2026. The company reported R$0.001 earnings per share for the quarter.

Is Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh pay dividends?

Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh does not currently pay dividends.

What is Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh’s EPS estimate?

Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh have?

Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh has 540,632,000 shares outstanding.

What happened to Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh’s price movement after its last earnings report?

Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh reported an EPS of R$0.001 in its last earnings report. Following the earnings report the stock price went up 4.322%.

Which hedge fund is a major shareholder of Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh?

Currently, no hedge funds are holding shares in BR:AMGN34

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh (AMGN34) Earnings & Revenues

Historic Earnings Reports

AMGN34 Net sales Breakdown

12.01% Prolia
6.06% ENBREL
5.67% XGEVA
8.21% Repatha
6.16% Otezla
5.18% TEPEZZA
5.71% EVENITY
3.84% KYPROLIS
4.15% Nplate
3.78% Aranesp
4.24% BLINCYTO
3.65% KRYSTEXXA
3.20% Vectibix
4.02% TEZSPIRE
19.76% Other products
4.36% Other revenues

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	15	1	6
Technical Analysis	3	1	6
Moving Averages	12	0	0

Technical Analysis >

Similar Stocks

Stocks similar to BR:AMGN34
Company	Price & Change	Follow
BR:BMYB34Bristol-Myers Squibb Company Shs Unsponsored Brazilian Depository Receipt Repr 1 Sh
BR:GILD34Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh
BR:MRCK34Merck & Co., Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.125 Sh
BR:PFIZ34Pfizer Inc Shs Unsponsored Brazilian Depository Receipts Repr 0.25 Sh
BR:VRTX34Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh

Compare BR:AMGN34 Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft